Kornimate/medical-research-clean huggingface dataset:
multifocal lens centration and its effect on visual performance in a presbyopic population

Conditions: Presbyopia

Summary: the purpose of this study is to use a corneal topographer, a device that is readily available in most optometric practices, in order to determine the position of the multifocal (mf) contact lens (cl) optics in relation to the optics of the eye. the specific purpose of this study is to evaluate if there is a relationship between the positioning of the optics of the study lenses and the objective and subjective visual performance as well as participant satisfaction. the mf cl lenses will be fitted to two groups of participants (previously unsuccessful vs. currently successful mf cl wearers). hypotheses * the measurement of the power distribution acquired from the medmont e300 corneal topographer is effective in determining mf cl lens centration and is a predictor of mf cl success. * there is a difference in mf cl centration, determined by corneal topography, between successful and unsuccessful mf cl wearers. * mf cl centration, determined by corneal topography, is correlated with visual performance, determined by ocular aberrometry, measures of visual acuity and subjective satisfaction.


Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: 1. is at least 42 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. is willing and able to follow instructions and maintain the appointment schedule; 4. has previous experience with wearing mf cls; 5. is able to be successfully fitted with all study lenses; 6. has a vertex-corrected spherical distance prescription of +6.00 to 8.00d (inclusive) in both eyes; 7. has a spectacle cylinder ≤0.75d in both eyes; 8. requires a reading addition of ≥+1.00d; exclusion criteria: a person will be excluded from the study if he/she: 1. is participating in any concurrent clinical or research study; 2. has any known active\* ocular disease and/or infection; 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. has a known sensitivity to the diagnostic pharmaceuticals to be used in the study; 6. is pregnant, lactating or planning a pregnancy at the time of enrolment; 7. is aphakic; 8. has undergone refractive error surgery; 9. has monocular best-corrected va of worse than 20/30 in each eye; 10. has amblyopia or strabismus; 11. has anisometropia \>2d between both eyes * for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
long term extension study evaluating safety, tolerability and immunogenicity of acc-001 in subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to assess the long term safety, tolerability, and immunogenicity of acc-001, an investigational active immunization product+, in subjects with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * subjects randomized under previous 3134k1-200 study (nct00479557) and met all inclusion/and none of the exclusion criteria * screening brain mri scan is consistent with the diagnosis of ad ' mini-mental state examination (mmse) score ≥10 exclusion criteria: * significant neurological disease other than alzheimer's disease * brain mri evidence of vasogenic edema (ve) during the preceding 3134k1 200 study (nct00479557) * clinically significant systemic illness
the safety, tolerability and efficacy of multiple subcutaneous injections of shr-1209 in subjects with hyperlipidemia

Conditions: Hyperlipidemia

Summary: this is a randomized, double-blind, placebo- controlled phaseⅰb/ⅱclinical study. totally 108 subjects are planned to enrolled with 36 subjects in three low-dose groups (group 1, group 2 and group 3) and 72 subjects in three high-dose groups (group 4, group 5, and group 6).12 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each low-dose group, randomly given shr-1209 or placebo treatment at a ratio of 5:1. 24 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each high-dose group, randomly given shr-1209 or placebo treatment at a ratio of 5:1. the primary objective of this study is to evaluate the safety, tolerability, and efficacy of multiple subcutaneous injections of shr-1209 in hyperlipidemia subjects treated with stabilized dose of statin. groups detail as follows: 1. shr-1209 dose 1 /placebo frequence 1 2. shr-1209 dose 2 /placebo frequence 2 3. shr-1209 dose 3 /placebo frequence 3 4. shr-1209 dose 4 /placebo frequence 1 5. shr-1209 dose 5 /placebo frequence 2 6. shr-1209 dose 6 /placebo frequence 3


Eligibility criteria:
inclusion criteria: 1. age ≥18 and ≤65 years old; 2. subjects who are receiving statin therapy at the time of screening or who are eligible for statin therapy can randomized to receive a stable dose of statin therapy for more than 28 days and are willing to maintain stable statin therapy in this study; 3. low-density lipoprotein cholesterol (ldl-c) level ≥2.6mmol/l of subjects who receiving statin and/or other lipid-lowering therapy at the time of screening, or ldl-c≥ 3.4mmol/l of subjects who didn't receive any-lowering therapy at the time of screening, and ldl-c still ≥2.6mmol/l before randomization; 4. fasting triglycerides ≤4.5 mmol/l; 5. body mass index (bmi) ≥18 and ≤ 35 kg/m2; 6. signed informed consent. exclusion criteria: 1. a clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar experimental drugs; 2. diagnosis of homozygous familial hypercholesterolemia; 3. new york heart association (nyha) defined ⅱ - ⅳ history of heart failure; 4. history of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina), or percutaneous coronary intervention, or coronary artery bypass graft, or history of cerebrovascular disease, within 12 months prior to screening; 5. uncontrolled severe arrhythmias that are not controlled by drugs or other therapy within 12 months prior to enrollment; 6. uncontrolled hypertension (systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmhg); 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) or gamma pancreatic acyl transferase (ggt), more than 2.5x uln; 8. subjects with previous malignant tumor diseases. etc.
investigating burnout in intensive care in middle incoming turkey

Conditions: Burnout Syndrome

Summary: turkey is a developing country and its intensive care infrastructure is worse than developed countries. the staff is very busy at work. intensive care has become a new science. we wanted to investigate burnout syndrome among physicians and other health care workers who are starting to work at a new intensive care medicine. intensive care specialists in turkey do not work in intensive care centers where they want. this may have a negative effect on physicians.

burnuot health practices are more common than the normal group. the data about turkey are limited. in developing societies, there are often no protocols in intensive care. there are no teams again during intensive care. all work is done by physicians and other health workers. this may adversely affect health care workers. intensive care science is new. the training first started in 2013. the newly graduated heavy-duty specialists can work where they do not want. the workload of the health workers working in the intensive care unit is high. we wanted to investigate burnout on healthcare workers in turkey.

Eligibility criteria:
inclusion criteria: fellow, nursing, specialist and academics working intensive care medicine exclusion criteria:
multimodal assessment of frailty in acute stroke patients

Conditions: Stroke; Frailty

Summary: the goal of this study is to investigate the influence of frailty on clinical and stroke characteristics, treatment and outcomes in patients with acute stroke. the main questions it aims to answer are: 1. how prevalent is frailty in patients with stroke? 2. which impairments (e.g. undernutrion, impaired mobility, laboratory markers) contribute to frailty? 3. is the outcome of frail patients worse than those without? 4. are in-hospital complications more frequent in frail patients than those without?

stroke is one of the most common causes of disability and mortality worldwide. a recognized complication in stroke patients is frailty, which is associated with increased costs, poorer prognosis, and higher mortality rates. however, there is currently no uniform definition or diagnostic criteria for frailty in stroke patients, and there is a need for standardized frailty assessments in this patient population. the aim of this study is to determine the prevalence of frailty in stroke patients at the stroke unit of the university hospital giessen and to analyze the associated characteristics and impacts on clinical outcomes. a multimodal frailty assessment will be conducted to capture a wide range of frailty features and investigate their significance. the study includes all stroke patients admitted to the certified stroke- unit of the university hospital giessen within a 3-month period. there are no inclusion criteria related to age, gender, or type of stroke. the multimodal frailty assessment encompasses determining appropriate blood values (e.g., crp, albumin), assessing muscle strength/mass through handheld dynamometry and sonographic muscle diameter, utilizing scores like the clinical frailty scale (cfs) and the groningen frailty indicator (gfi), evaluating nutritional status (bmi), collecting image-based frailty data (e.g., sarcopenia, cerebral white matter lesions, lacunar strokes, brain atrophy), and conducting suitable one-year follow-ups. additionally, demographic and clinical data such as age, gender, type of stroke, and treatment details will be recorded. the primary outcome is the prevalence of frailty among stroke patients. secondary outcomes include the characteristics and impacts of frailty in stroke patients, including correlations between various frailty features and clinical outcomes such as length of hospital stay, mortality, and functional outcome.

Eligibility criteria:
inclusion criteria: * treated at the certified stroke-unit of the dpt. of neurology, university hospital giessen * diagnosis of ischemic (including transient ischemic attack) or hemorrhagic stroke exclusion criteria: * withdrawal of care within 24 hours after admission

Keywords: frailty outcome elderly
picturerx: an intervention to reduce latino health disparities

Conditions: Medication Adherence; Diabetes

Summary: the purpose of this randomized controlled trial is to evaluate the effect of spanish-language illustrated medication instructions (picturerx cards), compared to traditional medication instructions, on latinos' understanding of their medication regimens. the study will also assess the effect on self-reported medication adherence. patients with diabetes who attend participating clinics are eligible. the target sample size is 200.


Eligibility criteria:
inclusion criteria: * diabetes * latino, spanish speaker * be at least 18 years old * must be taking at least 1 chronic medication exclusion criteria: * too ill to participate in an interview * do not have a telephone * having visual acuity worse than 20/50 via rosenbaum visual acuity exam (eyechart) * inability to communicate in either spanish or english * overt psychiatric illnesses, overt delirium or dementia

Keywords: picturerx health literacy limited english proficiency latinos spanish
the correlation between outcome and infarct growth in patients with acute ischemic stroke

Conditions: Ischemic Stroke

Summary: previous research has shown there wasn't inevitable relationship between mismatch area and infarct growth according to volumetric-subtraction mismatch volume.the recently published on stroke paper has proposed coregistration mismatch to calculate the mismatch to replace ischaemic penumbra, and it reignites hope for clinical application of the pwi/dwi mismatch. but the correlation between the mismatch, calculated by coregistration mismatch method,and the clinical outcome of the patients with acute ischemic stroke is still unknown. so the investigators plan to conduct a prospective observational cohort study.

nihss,mrs and mr pwi/dwi/mra are performed within 48 hours of stroke onset and final mr t2/flair image at ≈1 month. and then,volumetric-subtraction mismatch and coregistered mismatch will be calculated,respectively.finally,we will assess and compare the volumetric-subtraction mismatch and coregistered mismatch, and to clarify which method match the clinical outcome more better.

Eligibility criteria:
inclusion criteria: * aged eighteen or above * acute middle cerebral artery ischemic stroke * stroke onset within 48 hours * included a complete set of initial mr images and final outcome mr images up to 1 months exclusion criteria: * history of stroke in the past 6 weeks * pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mrs score greater than 3 * ct evidence of the following conditions before enrollment: significant mass effect with midline shift evidence of intracranial hemorrhage * with contraindication to mr such as severe allergy to contrast media

Keywords: stroke ischaemic stroke cerebral infarction cerebrovascular disorders brain diseases nervous system diseases vascular diseases brain infarction brain ischemia mismatch pwi/dwi mismatch ischaemic penumbra image analysis
d-cycloserine augmentation of behavior therapy for individuals with body dysmorphic disorder

Conditions: Body Dysmorphic Disorder

Summary: the purpose of the study is to conduct a double-blind, placebo-controlled study of d-cycloserine (dcs) augmentation of behavior therapy in individuals with body dysmorphic disorder (bdd). specifically, we intend to randomize 50 individuals with bdd to receive either dcs (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * primary diagnosis of body dysmorphic disorder as determined by dsm-iv criteria * bdd yale-brown obsessive compulsive scale score greater than or equal to 24 * females of childbearing potential must have a negative urinary beta-hcg test * subjects currently taking psychotropic medication must be on a stable does for at least two months prior to initiating study procedures exclusion criteria: * pregnant or breastfeeding women will be excluded * people taking medications that may interfere with dcs * history of seizure disorder or other serious medical illnesses such as cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease * comorbid psychiatric diagnoses (alcohol dependence, bipolar disorder, psychosis, borderline personality disorder, organic mental disorder, or development disorder). if subjects have any other comorbid disorder, the bdd symptoms have to be the primary concern. * persons taking medications that may lower seizure threshold, including clozapine, pethidine, and the following antibiotics in high dosage: penicillins, cephalosporins, amphotericin, and imipenem * those deemed to pose a serious suicidal or homicidal threat will be excluded * current psychotherapy or failure to benefit from ten or more sessions of previous erp treatment is a rule-out
changes associated with h. pylori and gastric carcinogenesis

Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Summary: this is a research study for patients who currently have or previously had an h. pylori infection or who have gastric or esophageal cancer and who plan to undergo an endoscopy as part of their care. the purpose of this study is to find out how and why h. pylori infections can cause progression to gastric cancer and if it's possible for intervention prior to this progression.

h. pylori infection is a prevalent environmental cause of gastric cancer. the molecular mechanisms of carcinogenesis due to h. pylori remain unexplained and consequences of infection are variable and unpredictable. the aim of this research is to examine the rna transcriptome of gastric cancer mucosa (gastric mucosa is the mucus membrane of the stomach), in patients with h. pylori infection and examine the spectrum of disease associated with infection. we will also examine bacterial content of samples to pinpoint the specific h. pylori strain(s) and the stomach microbial profile to correlate with the gastric mucosal transcriptome and predisposition of gastric cancer. patients with prior or current active h. pylori infection who are planning to under endoscopic evaluation will be eligible for participation. from these patients, we plan to take up to four additional biopsies from each area of stomach already being sampled. the biopsies will be used for next-generation rna and dna sequencing and novel bioinformatics analyses. the analysis will be performed at weill cornell medical college by doron betel, phd. the sequencing will be performed in the epigenetics core laboratory under the supervision of doron betel, who will be working closely with the principal investigator, manish a. shah, m.d. examination of the genetic impact of h. pylori infection in patients may expose genetic factors that influence gastric cancer carcinogenesis and give deeper insight into molecular pathways that serve as candidate biomarkers for gastric cancer carcinogenesis. our goal is to distinguish patients with chronic h. pylori infection who are at risk of subsequently developing gastric cancer from the vast majority of patients with h. pylori infection who do not develop malignancy.

Eligibility criteria:
inclusion criteria: * patient must be 18 years or older * patient must have active or prior h. pylori infection, or have been treated for h.pylori infection in the past, as assessed by elisa (not applicable for the subset of patient controls) or have gastric or esophageal cancer or have barrett's esophagus * patients must be eligible for and are planning to undergo a routine upper endoscopy and tissue biopsy * patients must sign informed consent exclusion criteria: * prior history of upper gi bleed (within 3 months) * bleeding disorder or coagulopathy * recent stroke or myocardial infarction (within 3 months)
effectiveness of a cognitive remediation intervention based on virtual reality for promotion of cognitive functioning and participation in daily life among persons with affective disorder

Conditions: Affective Disorder

Summary: the purpose of this study is to test the efficacy of remedial cognitive intervention using the functional brain trainer vr (fbt, intendo ©) to improve cognitive functioning, participation in daily life occupations, and functional capacity in the field of iadl among people with affective disorders receiving inpatient and daycare mental-health services.

this study is an experimental study, in a pre-post design with a control group, the sampling is convenience. the study will include 40 people aged 18-60 with a diagnosis of affective disorder based on dsm-5. inclusion criteria: age 18-60, diagnosis of major depression or bipolar disorder based on dsm-5; mood stabilizing medication for at least 2 weeks, exclusion criteria: neurological disorders and neurodevelopmental conditions in addition to mental health diagnosis; physical disability in addition to mental health conditions; psychotic state; active substance abuse; custodian. they will be recruited from active inpatient and daycare wards of the "geha mental health center", israel and will be randomly allocated into two groups: experimental and control. an experimental group will attend 6 vr based cognitive remediation sessions of 30 minutes for training response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence. the control group will complete 6 sessions of 30 minutes of low-tech (paper and pencil tasks) remedial training of the same cognitive components. these in addition to routine care. the evaluation for symptoms severity, cognition, functional capacity and participation in daily life activities will be conducted at the beginning of the study and after about 4 weeks.

Eligibility criteria:
inclusion criteria: * age 18-60, * diagnosis of major depression or bipolar disorder based on dsm-5; * mood stabilizing medication for at least 2 weeks, exclusion criteria: * neurological disorders and neuro-developmental conditions in addition to mental health diagnosis; * physical disability in addition to mental health conditions; * psychotic state; * active substance abuse; * custodian

Keywords: affective disorder
convalescent plasma for the treatment of patients with severe covid-19 infection

Conditions: COVID-19 Infection

Summary: this is a multicenter, phase 2 study, to assess the efficacy of the treatment with convalescent plasma in patients with severe covid-19 infection.

convalescent plasma will be collected by plasmapheresis from patients fully recovered from covid-19 infection and will be administered in patients with severe covid-19 infection. the results will be compared with an historical matched control.

Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. confirmed sars-cov2 infection by pcr of the nasal/pharyngeal swab, sputum, bal 3. onset of the disease symptoms no more than 12 days before the inclusion of the patients in the trial 4. severe covid-19 infection as determined with one of the following: * respiratory rate 30/min * oxygen hemoglobin saturation sat 93 * crp \>1.5 (upper normal limit \<0.5) * ferritin value \>100 * ratio of pao2:fio2 \<300mmhg * pulmonary infiltrates in chest x-ray or chest ct scan \>50% during 24-48 hours 5. life threatening infection as determined by one of the following: * respiratory failure * septic shock * multiple organ failure 6. signature of informed consent by the patient or legal representative patients fulfilling criteria 1, 2, 3, 6 and one of criteria 4 or 5 will be eligible for the study. exclusion criteria: 1. critical illness due to progressive covid-19 with expected survival time \<48 hours 2. intubated patients \>72 hours 3. chronic heart failure nyha 3 and/or preexisting left ventricular ejection fraction 30% 4. cardiovascular failure requiring 0.5μg/kg/min nor-adrenaline or equivalent or more than 2 types of vasopressor medication 5. liver cirrhosis child c 6. liver failure with bilirubin \>5x uln and increase of alt/ast (at least one \>10x uln) 7. previous history of allergic reaction to blood or blood products transfusion 8. known iga deficiency 9. pregnancy 10. breast feeding women 11. pulmonary edema